4//SEC Filing
Duchemin Jeffrey 4
Accession 0001209191-18-046059
CIK 0001123494other
Filed
Aug 8, 8:00 PM ET
Accepted
Aug 9, 5:00 PM ET
Size
23.0 KB
Accession
0001209191-18-046059
Insider Transaction Report
Form 4
Duchemin Jeffrey
Chief Executive Officer
Transactions
- Sale
Common Stock
2018-08-08$6.35/sh−5,500$34,925→ 790,742 total - Exercise/Conversion
Common Stock
2018-08-09$4.31/sh+44,500$191,795→ 835,242 total - Sale
Common Stock
2018-08-07$6.07/sh−100,000$607,000→ 790,742 total - Sale
Common Stock
2018-08-09$6.41/sh−44,500$285,245→ 790,742 total - Exercise/Conversion
Stock option (right to buy)
2018-08-07−100,000→ 400,000 totalExercise: $4.31From: 2016-11-18Exp: 2023-11-18→ Common Stock, par value $0.01 per share (500,000 underlying) - Exercise/Conversion
Stock option (right to buy)
2018-08-09−44,500→ 350,000 totalExercise: $4.31From: 2016-11-18Exp: 2023-11-18→ Common Stock, par value $0.01 per share (394,500 underlying) - Exercise/Conversion
Common Stock
2018-08-07$4.31/sh+100,000$431,000→ 890,742 total - Exercise/Conversion
Common Stock
2018-08-08$4.31/sh+5,500$23,705→ 796,242 total - Exercise/Conversion
Stock option (right to buy)
2018-08-08−5,500→ 394,500 totalExercise: $4.31From: 2016-11-18Exp: 2013-11-18→ Common Stock, par value $0.01 per share (400,000 underlying)
Footnotes (9)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (continued in footnote 3 below)
- [F3](continuation of footnote 3 above) (f) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 198,842 shares of common stock held by the Reporting Person.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
- [F5]Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person.
- [F6]Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 104,342 shares of common stock held by the Reporting Person.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).
- [F8]Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 143,342 shares of common stock held by the Reporting Person.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).
Documents
Issuer
HARVARD BIOSCIENCE INC
CIK 0001123494
Entity typeother
Related Parties
1- filerCIK 0001585223
Filing Metadata
- Form type
- 4
- Filed
- Aug 8, 8:00 PM ET
- Accepted
- Aug 9, 5:00 PM ET
- Size
- 23.0 KB